Topic Paragraphs
Don't delay, get your COVID-19 vaccine or booster today!
Getting vaccinated or receiving a booster if you’re already vaccinated is the best thing you can do to help protect yourself, family and friends.
Vaccines.gov
FDA 2021 Year in Review - Working for You
Featured Topics
New Era of Smarter Food Safety
A new approach to food safety that recognizes and builds on the progress made in the past but looks towards what processes and tools will be needed for the future.
Fostering Drug Competition
Increasing the availability of generic drugs helps to create competition in the marketplace, helping make treatment more affordable and increasing access to healthcare for more patients.
Combating the Opioid Crisis
FDA takes actions to combat prescription opioid abuse.
Recalls, Market Withdrawals, & Safety Alerts
The FDA provides information gathered from press releases and other public notices about certain recalls of FDA-regulated products. Not all recalls have press releases or are posted on this website
Jan 19
Amy’s Kitchen Voluntarily Issues Allergy Alert on Undeclared Milk in a Single Lot of Vegan Organic Rice Mac & Cheeze
Food & Beverages
Jan 19
BCS International Corp. Issues Alert on Undeclared Sulfites in “Dr. Snack Goji Berry”
Food & Beverages
Jan 19
Frozen Food Development Recalls Lidl Branded Chopped Spinach Because of Possible Health Risk
Food & Beverages
Paragraph Header
FDA VOICES: PERSPECTIVES FROM FDA EXPERTS
What FDA’s Foods Program Achieved in 2021 to Protect Consumers and the Food Supply
Despite the unprecedented challenges we’ve all faced during the COVID-19 pandemic, 2021 was another important year for FDA's Foods Program.
Many Important Drugs Approved in 2021 as COVID-19 Pandemic Continues
CDER approved a wide variety of safe and effective new drug therapies in 2021 despite challenges brought on by the ongoing COVID-19 pandemic.
Looking Ahead to 2022 as FDA’s Center for Devices and Radiological Health Manages a Sustained Increase in Workload
While CDRH’s response to the pandemic remains a top priority, we anticipate a gradual transition back toward normal review timelines in 2022.
Recently Published Guidances
Jan 26
Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments; Draft Guidance for Industry
Drugs
Jan 26
Good ANDA Submission Practices Guidance for Industry
Drugs
Jan 26
Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation
Biologics, Medical Devices